We are analyzing https://link.springer.com/article/10.1007/s11926-012-0254-6.

Title:
Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development? | Current Rheumatology Reports
Description:
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

article, google, scholar, pubmed, cas, systemic, lupus, belimumab, erythematosus, cells, sle, baff, cell, immunol, stimulator, arthritis, stohl, blys, patients, lymphocyte, april, rheum, factor, phase, tumor, mice, development, exp, med, disease, study, differences, necrosis, receptor, bliss, privacy, cookies, content, antibody, safety, bcma, jacob, human, murine, regulatory, furie, publish, research, search, biologic,

Topics {✒️}

neutralizing anti-b-lymphocyte stimulator month download article/chapter b-cell survival factor ifn-α-exaggerated disease b-cell autoimmune disease systemic lupus erythematosus systemic lupus erythematosus full article pdf sle responder index privacy choices/manage cookies b-lymphocyte stimulator cellular competition independent april-deficient mice humoral immune response caml-interacting member cell receptor repertoire european economic area jt merrill undergoing clinical testing antagonists subtly differ related subjects nucleic acids res baker kp enter forbidden follicular marginal zone niches progressive multifocal leukoencephalopathy 1500 patient-year experience lupus-prone sustained disease improvement cell maturation antigen receptor homologues bcma conditions privacy policy tnf homologue implicated concurrent neutralization/elimination mol cell biol article stohl april neutralization/elimination nonselective baff blockade excess baff rescues post-hoc analysis quinn iii wj dose-escalating trial proinflammatory th17 cells pathogenic th17 cells lymphocyte stimulator enhancement multicenter phase ib article log human genome sciences baff mediates survival dose-ranging study

Questions {❓}

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
         description:For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.
         datePublished:2012-05-01T00:00:00Z
         dateModified:2012-05-01T00:00:00Z
         pageStart:303
         pageEnd:309
         sameAs:https://doi.org/10.1007/s11926-012-0254-6
         keywords:
            APRIL
            Atacicept
            BCMA
            Belimumab
            Blisbimod (A-623)
            BLyS/BAFF
            BR3
            Systemic lupus erythematosus
            Tabalumab (LY2127399)
            TACI
            SLE
            Rheumatology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11926-012-0254-6/MediaObjects/11926_2012_254_Fig1_HTML.gif
         isPartOf:
            name:Current Rheumatology Reports
            issn:
               1534-6307
               1523-3774
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Science Inc.
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:William Stohl
               affiliation:
                     name:University of Southern California Keck School of Medicine
                     address:
                        name:Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
      description:For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.
      datePublished:2012-05-01T00:00:00Z
      dateModified:2012-05-01T00:00:00Z
      pageStart:303
      pageEnd:309
      sameAs:https://doi.org/10.1007/s11926-012-0254-6
      keywords:
         APRIL
         Atacicept
         BCMA
         Belimumab
         Blisbimod (A-623)
         BLyS/BAFF
         BR3
         Systemic lupus erythematosus
         Tabalumab (LY2127399)
         TACI
         SLE
         Rheumatology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11926-012-0254-6/MediaObjects/11926_2012_254_Fig1_HTML.gif
      isPartOf:
         name:Current Rheumatology Reports
         issn:
            1534-6307
            1523-3774
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Science Inc.
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:William Stohl
            affiliation:
                  name:University of Southern California Keck School of Medicine
                  address:
                     name:Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Rheumatology Reports
      issn:
         1534-6307
         1523-3774
      volumeNumber:14
Organization:
      name:Current Science Inc.
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Southern California Keck School of Medicine
      address:
         name:Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:William Stohl
      affiliation:
            name:University of Southern California Keck School of Medicine
            address:
               name:Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(164)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Bliss.js
Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.05s.

LINK . SPRINGER . COM {}